Julia Boll, MD
Vascular Surgery · Nashville, TNNPI 1629393004
Payments from drug & device makers
What this record shows
This record is dominated by other: $22,229 of the $35,819 with a category attached, or 62.1%. Angiodynamics, Inc. accounts for 62.1% of it on its own, with 31 other manufacturers making up the rest. 2025 is the largest year on record at $22,497, 7.9 times the $2,842 reported in 2019.
Across 223 payments — averaging $160.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$22K
- W. L. Gore & Associates, Inc.$2K
- Endologix LLC$2K
- Medtronic$1K
- Abbott$1K
- Silk Road Medical, Inc.$1K
- plus $6K from 26 others
What the payments were for
- Consulting fees$4001%
- Travel & lodging$330%
- Food & beverage$13,15737%
- Other$22,22962%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 5 | $22,248 |
| W. L. Gore & Associates, Inc. | 24 | $1,924 |
| Endologix LLC | 5 | $1,541 |
| Medtronic(2 entities) | 16 | $1,423 |
| Abbott | 17 | $1,218 |
| Silk Road Medical, Inc. | 14 | $1,061 |
| Boston Scientific | 26 | $1,043 |
| Penumbra, Inc. | 25 | $956 |
| Cook Medical LLC | 18 | $905 |
| Shockwave Medical, Inc | 9 | $785 |
| Inari Medical, Inc. | 11 | $586 |
| Atrium Medical Corporation | 1 | $400 |
| Aroa Biosurgery Incorporated | 4 | $303 |
| Abiomed | 2 | $298 |
| Lemaitre Vascular, Inc. | 6 | $134 |
| Reflow Medical Inc | 1 | $123 |
| Innovation Technologies Inc | 4 | $115 |
| Bolton Medical Inc | 4 | $114 |
| Smith+Nephew | 7 | $111 |
| Surmodics, Inc. | 5 | $108 |
| Argon Medical Devices, Inc. | 3 | $85 |
| Johnson & Johnson(2 entities) | 3 | $67 |
| Bard Peripheral Vascular, Inc. | 3 | $65 |
| Atricure, Inc. | 2 | $40 |
| Merck | 1 | $30 |
| GSK | 1 | $25 |
| Cagent Vascular Inc | 1 | $23 |
| Kerecis Limited | 1 | $22 |
| Solventum Corporation | 1 | $19 |
| Bsn Medical Inc | 1 | $17 |
| KCI USA, Inc. | 1 | $16 |
| Endogastric Solutions, Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$22,229
- ENROUTE Transcarotid Neuroprotection System$1,506
- Ovation$1,188
- ENROUTE Transcarotid Stent$888
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$626
- Endurant$578
- GORE EXCLUDER AAA Endoprosthesis$470
- VIABAHN Endoprosthesis with Heparin Bioactive Surface$467
- Indigo System$427
- FLIXENE$400
- FLOWTRIEVER CATHETER, S$375
- CT THROMBECTOMY SYSTEM KIT$375
- AFX$353
- ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter$352
- Zilver PTX$347
- Impella$298
- EXCLUDER Conformable AAA Endoprosthesis with Active Control$286
- JETI$271
- ENHANCE Transcarotid Peripheral Access Kit$223
- ENROUTE .014 Guidewire$223
How this compares
$35,819 in reported general payments places this provider in the 85th percentile of 117 vascular surgery providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 47 | $38,961 |
| ClopidogrelClopidogrel Bisulfate | 125 | $1,459 |
| Cilostazol | 18 | $335 |
| Rosuvastatin Calcium | 11 | $105 |
| Atorvastatin Calcium | 19 | $90 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $67 | $38,96147 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 117 vascular surgery providers in Tennessee.
Other vascular surgery in Nashville
- Daniel ClairNashville$993K
- Patrick StoneNashville$46K
- Allen LeeNashville$39K
- Thomas NaslundNashville$31K
- Lauren FryeNashville$20K
- Patrick RyanNashville$19K
- Jim Bob FaulkNashville$13K
- Mary NallyNashville$10K
- Sergio Sastriques DunlopNashville$10K
- Ziad Al AdasNashville$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.